ABCL AbCellera Biologics Inc. - Fundamental Analysis
BEARISH
Sign in to save
Save this symbol to a watchlist or track a position.
ABCL Stock | Fundamental Analysis & Investment Insights
NASDAQ
Healthcare
Biotechnology
Current Price
Live
$3.1
Analyst Target
$9.83
+217.2%
Upside
52W High
$6.51
52W Low
$1.89
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Feb 14, 2026
Market cap
$927.94M
P/E
N/A
ROE
-16.8%
Profit margin
N/A
Debt/Equity
0.15
Dividend yield
N/A
AI Analysis
Powered by advanced machine learning algorithms
Confidence Score
85%
Analysis Accuracy
ABCL's Advanced Deterministic Scorecard reveals significant financial distress, with a Piotroski F-Score of 1/9 indicating severe operational weakness and no Altman Z-Score available, raising bankruptcy risk concerns. Despite strong revenue growth of 37.6% YoY, the company reports a 0.00% profit margin, negative operating margin of -851.79%, and persistent losses, undermining profitability. The stock trades at a premium valuation (Price/Sales of 26.27) with no earnings or cash flow support, and its 5-year price decline of 93% reflects deep investor skepticism. Analysts rate it 'strong_buy' with a $9.83 target, but this optimism appears disconnected from current fundamentals. Insider activity is neutral, offering no conviction signal.
Key Strengths
37.6% year-over-year revenue growth indicates strong top-line momentum
High current and quick ratios (10.10 and 8.48) suggest strong short-term liquidity
Low debt-to-equity ratio (0.15) indicates conservative capital structure
Analyst consensus is 'strong_buy' with a significant price target upside
Recent quarterly earnings have shown occasional positive surprises (e.g., +26.5%)
Key Risks
Piotroski F-Score of 1/9 signals extreme financial distress and poor operational health
Negative operating margin (-851.79%) and zero profit margin indicate severe unprofitability
No positive free cash flow or operating cash flow data available, raising sustainability concerns
Stock has declined 93% over 5 years, reflecting prolonged investor skepticism
No dividend and no payout history, with no indication of future distribution capability
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
23
Weak
25
55
20
15
0
AI Verdict
Weak
Key drivers: Extremely low Piotroski F-Score (1/9), Negative profitability and operating margins, High valuation relative to earnings and cash flow, Lack of sustainable growth indicators beyond top-line revenue
Confidence
88%
Value
25/100
Ref P/E, PEG, Graham Number
Positives
- Low Price/Book ratio (0.96) suggests potential undervaluation on asset basis
Watchpoints
- Price/Sales of 26.27 is extremely high for a loss-making company
- No Graham Number or intrinsic value available due to negative earnings
- No cash flow or earnings to support valuation multiples
Future
55/100
Ref Growth rates
Positives
- 37.6% YoY revenue growth indicates strong market expansion potential
- Recent quarters show occasional earnings beat (e.g., +26.5%)
Watchpoints
- Forward P/E of -4.88 indicates continued losses expected
- Negative EPS growth (-11.8% YoY) and declining Q/Q EPS (-58.3%)
- No free cash flow or operating cash flow data to support growth sustainability
Past
20/100
Ref Historical trends
Positives
- Historical revenue growth has been volatile but generally positive
- Some quarters have exceeded expectations (e.g., +77.8% surprise in 2022)
Watchpoints
- Persistent losses over 21 quarters, including multiple large misses
- Negative ROE (-16.81%) and ROA (-10.43%) indicate poor capital efficiency
- 900% negative surprise in 2023 Q1 shows extreme forecasting challenges
Health
15/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Low debt-to-equity (0.15) and high current/quick ratios suggest strong liquidity
Watchpoints
- Piotroski F-Score of 1/9 is among the weakest possible, indicating severe financial distress
- No Altman Z-Score available, but the financial profile suggests distress risk
- Negative operating margin and lack of profitability undermine long-term viability
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- No dividend yield or payout ratio
- 0/100 dividend strength score reflects no income generation capability
- Negative earnings make dividend payment impossible
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$3.1
Analyst Target
$9.83
Upside/Downside
+217.2%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for ABCL and closest competitors.
Updated 2026-02-13
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
ABCL
AbCellera Biologics Inc.
Primary
|
-93.0% | -68.9% | -1.3% | -32.5% | -27.7% | -1.9% |
|
ARVN
Arvinas, Inc.
Peer
|
-84.4% | -59.8% | -28.4% | +64.4% | +5.9% | +5.7% |
|
AHG
Akso Health Group
Peer
|
-40.6% | +246.5% | +7.2% | -12.9% | +8.0% | +4.9% |
|
AMN
AMN Healthcare Services, Inc.
Peer
|
-72.8% | -78.8% | -26.3% | +3.5% | +28.0% | +7.7% |
|
ABUS
Arbutus Biopharma Corporation
Peer
|
-11.4% | +46.9% | +20.6% | +18.1% | -16.7% | +3.6% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-4.88
PEG Ratio
N/A
P/B Ratio
0.96
P/S Ratio
26.27
EV/Revenue
16.26
EV/EBITDA
-2.47
Market Cap
$927.94M
Profitability
Profit margins and return metrics
Profit Margin
N/A
Operating Margin
-851.79%
Gross Margin
N/A
ROE
-16.81%
ROA
-10.43%
Growth
Revenue and earnings growth rates
Revenue Growth
+37.6%
Earnings Growth
N/A
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.15
Low debt
Current Ratio
10.1
Strong
Quick Ratio
8.48
Excellent
Cash/Share
$1.66
Quarterly Earnings History
EPS performance vs analyst estimates
2026-02-24
$N/A
2025-11-06
$-0.19
-17.3% surprise
2025-08-07
$-0.12
+26.5% surprise
2025-05-08
$-0.15
-5.3% surprise
Healthcare Sector Comparison
Comparing ABCL against 146 companies in the Healthcare sector
(10 bullish, 60 neutral, 76 bearish)
Return on Equity (ROE)
-16.81%
This Stock
vs
-56.84%
Sector Avg
-70.4%
(Below Avg)
Debt to Equity
0.15
This Stock
vs
2.68
Sector Avg
-94.5%
(Less Debt)
Revenue Growth
37.6%
This Stock
vs
61.93%
Sector Avg
-39.3%
(Slower)
Current Ratio
10.1
This Stock
vs
3.47
Sector Avg
+191.5%
(Stronger)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
ABCL
AbCellera Biologics Inc.
|
BEARISH | $927.94M | - | -16.8% | -% | $3.1 | |
|
ARVN
Arvinas, Inc.
|
NEUTRAL | $946.35M | - | -10.2% | -18.7% | $12.89 | |
|
AHG
Akso Health Group
|
BEARISH | $818.31M | - | -80.3% | -% | $1.49 | |
|
AMN
AMN Healthcare Services, Inc.
|
BEARISH | $787.1M | - | -35.9% | -10.1% | $20.49 | |
|
ABUS
Arbutus Biopharma Corporation
|
BEARISH | $765.45M | - | -45.9% | -289.4% | $3.98 |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2025-12-18 | THERMOPYLAE HOLDINGS, LTD. | Beneficial Owner of more than 10% of a Class of Security | Gift | 225,000 | - |
| 2025-11-26 | MONTALBANO JOHN S. | Director | Purchase | 50,000 | $178,460 |
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
STRONG_BUY
6 analysts
Leerink Partners
2025-11-07
Outperform
Market Perform
Past News Coverage
Recent headlines mentioning ABCL from our newsroom.
Newest → oldest
No matching news yet.